SK Biopharmaceuticals Co., Ltd.
326030
Kedudukan dalam Saham
#4036
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Harga Saham
$51.65
Modal Pasaran
$4.05B
Perubahan (1 hari)
0.27%
Perubahan (1 tahun)
-30.95%
Negara
KR
Perdagangan SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
Bilangan saham terbitan bagi SK Biopharmaceuticals Co., Ltd. (326030)
Bilangan saham terbitan setakat June 2026: 78.31M
Menurut laporan kewangan terkini dan harga saham SK Biopharmaceuticals Co., Ltd., bilangan saham terbitan semasa ialah 78.31M. Pada akhir December 2024, syarikat mempunyai 78.31M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk SK Biopharmaceuticals Co., Ltd. (326030) dari 2011 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 78.31M | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 78.31M | 0.00% |
| 2023 | 78.31M | 0.00% |
| 2022 | 78.31M | 0.00% |
| 2021 | 78.31M | 9.12% |
| 2020 | 71.77M | 10.41% |
| 2019 | 65.00M | 4.44% |
| 2018 | 62.23M | 24.47% |
| 2017 | 50.00M | -0.04% |
| 2016 | 50.02M | 0.04% |
| 2015 | 50.00M | 1.08% |
| 2014 | 49.46M | 23.66% |
| 2013 | 40.00M | -0.03% |
| 2012 | 40.01M | 0.11% |
| 2011 | 39.97M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 224.21% |
US
|
|
| 396.00M | 405.66% |
US
|
|
| 478.91M | 511.54% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -20.59% |
NL
|
